Andrew D Clouston

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6989747/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis. JHEP Reports, 2022, 4, 100386.	4.9	22
2	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. Journal of Hepatology, 2022, 76, 1030-1041.	3.7	74
3	Therapeutic potential of macrophage colony-stimulating factor in chronic liver disease. DMM Disease Models and Mechanisms, 2022, 15, .	2.4	7
4	Consensus recommendations for histological criteria of autoimmune hepatitis from the International <scp>AlH</scp> Pathology Group. Liver International, 2022, 42, 1058-1069.	3.9	45
5	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. Hepatology, 2022, 76, 1150-1163.	7.3	15
6	Fifty years of impact on liver pathology: a history of the Gnomes. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 191-200.	2.8	0
7	IFN-λ therapy prevents severe gastrointestinal graft-versus-host disease. Blood, 2021, 138, 722-737.	1.4	21
8	Bone Marrow Regulatory T Cells Are a Unique Population, Supported by Niche-Specific Cytokines and Plasmacytoid Dendritic Cells, and Required for Chronic Graft-Versus-Host Disease Control. Frontiers in Cell and Developmental Biology, 2021, 9, 737880.	3.7	7
9	Regression of Fibrosis Stage With Treatment Reduces Long-Term Risk of Liver Cancer in Patients With Hemochromatosis Caused by Mutation in HFE. Clinical Gastroenterology and Hepatology, 2020, 18, 1851-1857.	4.4	26
10	Adult onset of genetic disorders in bile acid transport in the liver. Human Pathology, 2020, 96, 2-7.	2.0	7
11	Randomized, Placebo Controlled Trial of Experimental Hookworm Infection for Improving Gluten Tolerance in Celiac Disease. Clinical and Translational Gastroenterology, 2020, 11, e00274.	2.5	21
12	Standardising the interpretation of liver biopsies in nonâ€ a lcoholic fatty liver disease clinical trials. Alimentary Pharmacology and Therapeutics, 2019, 50, 1100-1111.	3.7	27
13	MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and Is Influenced by the Microbiota. Immunity, 2019, 51, 885-898.e7.	14.3	164
14	Inhibitors of class I histone deacetylases attenuate thioacetamideâ€induced liver fibrosis in mice by suppressing hepatic type 2 inflammation. British Journal of Pharmacology, 2019, 176, 3775-3790.	5.4	21
15	Donor T-cell–derived GM-CSF drives alloantigen presentation by dendritic cells in the gastrointestinal tract. Blood Advances, 2019, 3, 2859-2865.	5.2	21
16	IL-6 dysregulation originates in dendritic cells and mediates graft-versus-host disease via classical signaling. Blood, 2019, 134, 2092-2106.	1.4	29
17	Myeloid cell deletion of Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) induces non-alcoholic steatohepatitis. PLoS ONE, 2019, 14, e0225332.	2.5	6
18	Disease-free Survival and Local Recurrence After Laparoscopic-assisted Resection or Open Resection for Rectal Cancer. Annals of Surgery, 2019, 269, 596-602.	4.2	210

#	Article	IF	CITATIONS
19	Polycythemia Rubra Vera: Where Does the Truth Lie?. Gastroenterology, 2018, 155, e7-e8.	1.3	Ο
20	Pathologic Features of Hereditary Cholestatic Diseases. Surgical Pathology Clinics, 2018, 11, 313-327.	1.7	6
21	Underappreciation of nonâ€elcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis. Internal Medicine Journal, 2018, 48, 144-151.	0.8	80
22	Immunomodulatory liposomes targeting liver macrophages arrest progression of nonalcoholic steatohepatitis. Metabolism: Clinical and Experimental, 2018, 78, 80-94.	3.4	30
23	A critical role for donor-derived IL-22 in cutaneous chronic GVHD. American Journal of Transplantation, 2018, 18, 810-820.	4.7	45
24	Transplantation Pathology. , 2018, , 880-965.		3
25	Subclassification of hepatocellular adenomas: practical considerations in the implementation of the Bordeaux criteria. Pathology, 2018, 50, 593-599.	0.6	14
26	Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes. JCI Insight, 2018, 3, .	5.0	35
27	Recipient mucosal-associated invariant T cells control GVHD within the colon. Journal of Clinical Investigation, 2018, 128, 1919-1936.	8.2	78
28	Clinicopathological and molecular features of sessile serrated adenomas with dysplasia or carcinoma. Gut, 2017, 66, 97-106.	12.1	161
29	Acute graft-versus-host disease is regulated by an IL-17–sensitive microbiome. Blood, 2017, 129, 2172-2185.	1.4	63
30	Eomesodermin promotes the development of type 1 regulatory T (T _R 1) cells. Science Immunology, 2017, 2, .	11.9	118
31	Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease. Canadian Journal of Gastroenterology and Hepatology, 2017, 2017, 1-8.	1.9	17
32	Autophagy-dependent regulatory T cells are critical for the control of graft-versus-host disease. JCI Insight, 2016, 1, e86850.	5.0	43
33	Multiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established Biomarkers. PLoS ONE, 2016, 11, e0167001.	2.5	29
34	Serrated tubulovillous adenoma of the large intestine. Histopathology, 2016, 68, 578-587.	2.9	28
35	Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. American Journal of Human Genetics, 2016, 98, 830-842.	6.2	201
36	Corruption of dendritic cell antigen presentation during acute GVHD leads to regulatory T-cell failure and chronic GVHD. Blood, 2016, 128, 794-804.	1.4	49

#	Article	IF	CITATIONS
37	The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease. Liver International, 2016, 36, 370-377.	3.9	51
38	ldentification of the CIMP-like subtype and aberrant methylation of members of the chromosomal segregation and spindle assembly pathways in esophageal adenocarcinoma. Carcinogenesis, 2016, 37, 356-365.	2.8	46
39	Spatiotemporal Characterization of the Cellular and Molecular Contributors to Liver Fibrosis in a Murine Hepatotoxic-Injury Model. American Journal of Pathology, 2016, 186, 524-538.	3.8	28
40	Stereological Analysis of Liver Biopsy Histology Sections as a Reference Standard for Validating Non-Invasive Liver Fat Fraction Measurements by MRI. PLoS ONE, 2016, 11, e0160789.	2.5	20
41	Independent effects of diet and exercise training on fat oxidation in non-alcoholic fatty liver disease. World Journal of Hepatology, 2016, 8, 1137.	2.0	5
42	Tc17 cells are a proinflammatory, plastic lineage of pathogenic CD8+ T cells that induce GVHD without antileukemic effects. Blood, 2015, 126, 1609-1620.	1.4	98
43	Acute GVHD results in a severe DC defect that prevents T-cell priming and leads to fulminant cytomegalovirus disease in mice. Blood, 2015, 126, 1503-1514.	1.4	20
44	Deletion of Wntless in myeloid cells exacerbates liver fibrosis and the ductular reaction in chronic liver injury. Fibrogenesis and Tissue Repair, 2015, 8, 19.	3.4	36
45	Lack of efficacy of m <scp>TOR</scp> inhibitors and <scp>ACE</scp> pathway inhibitors as antifibrotic agents in evolving and established fibrosis in <i>Mdr2</i> ^{<i>â^'/â^'</i>} mice. Liver International, 2015, 35, 1451-1463.	3.9	5
46	<scp>ELF</scp> score ≥9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity. Liver International, 2015, 35, 1673-1681.	3.9	60
47	Aspartate aminotransferase to platelet ratio and fibrosisâ€4 as biomarkers in biopsyâ€validated pediatric cystic fibrosis liver disease. Hepatology, 2015, 62, 1576-1583.	7.3	85
48	Lung parenchyma-derived IL-6 promotes IL-17A–dependent acute lung injury after allogeneic stem cell transplantation. Blood, 2015, 125, 2435-2444.	1.4	73
49	Australian clinical practice guidelines for the diagnosis and management of <scp>B</scp> arrett's esophagus and early esophageal adenocarcinoma. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 804-820.	2.8	104
50	Well-differentiated hepatocellular neoplasm of uncertain malignant potential—reply. Human Pathology, 2015, 46, 635-636.	2.0	6
51	Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 638-645.	2.8	7
52	Effect of resveratrol on experimental non-alcoholic steatohepatitis. Pharmacological Research, 2015, 95-96, 34-41.	7.1	33
53	Clonal expansion of hepatocytes with a selective advantage occurs during all stages of chronic hepatitis <scp>B</scp> virus infection. Journal of Viral Hepatitis, 2015, 22, 737-753.	2.0	73
54	Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer. JAMA - Journal of the American Medical Association, 2015, 314, 1356.	7.4	835

#	Article	IF	CITATIONS
55	A clinicopathological and molecular analysis of 200 traditional serrated adenomas. Modern Pathology, 2015, 28, 414-427.	5.5	140
56	Experimental hookworm infection and gluten microchallenge promote tolerance in celiac disease. Journal of Allergy and Clinical Immunology, 2015, 135, 508-516.e5.	2.9	163
57	Analysis of the intrahepatic ductular reaction and progenitor cell responses in hepatitis C virus recurrence after liver transplantation. Liver Transplantation, 2014, 20, 1508-1519.	2.4	25
58	Nonâ€alcoholic steatohepatitis weakens the acute phase response to endotoxin in rats. Liver International, 2014, 34, 1584-1592.	3.9	13
59	Ductular reaction in hereditary hemochromatosis: The link between hepatocyte senescence and fibrosis progression. Hepatology, 2014, 59, 848-857.	7.3	68
60	The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology, 2014, 59, 1393-1405.	7.3	344
61	Critical Appraisal of the Diagnosis of the Sessile Serrated Adenoma. American Journal of Surgical Pathology, 2014, 38, 158-166.	3.7	94
62	Links Between Hepatic Fibrosis, Ductular Reaction, and Progenitor Cell Expansion. Gastroenterology, 2014, 146, 349-356.	1.3	256
63	New Paradigms in the Histopathology of NAFLD. Current Hepatology Reports, 2014, 13, 81-87.	0.9	0
64	Pathology of the liver sinusoids. Histopathology, 2014, 64, 907-920.	2.9	63
65	188. Cytokine, 2014, 70, 73.	3.2	0
66	Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function. American Journal of Physiology - Renal Physiology, 2014, 307, G295-G301.	3.4	44
67	Well-differentiated hepatocellular neoplasm of uncertain malignant potential: proposal for a new diagnostic category. Human Pathology, 2014, 45, 658-660.	2.0	58
68	CSF-1–dependant donor-derived macrophages mediate chronic graft-versus-host disease. Journal of Clinical Investigation, 2014, 124, 4266-4280.	8.2	173
69	Senescent human hepatocytes express a unique secretory phenotype and promote macrophage migration. World Journal of Gastroenterology, 2014, 20, 17851-17862.	3.3	57
70	Excess iron modulates endoplasmic reticulum stress-associated pathways in a mouse model of alcohol and high-fat diet-induced liver injury. Laboratory Investigation, 2013, 93, 1295-1312.	3.7	89
71	Induced Regulatory T Cells Promote Tolerance When Stabilized by Rapamycin and IL-2 In Vivo. Journal of Immunology, 2013, 191, 5291-5303.	0.8	101
72	Portal, but not lobular, macrophages express matrix metalloproteinaseâ€9: association with the ductular reaction and fibrosis in chronic hepatitis C. Liver International, 2013, 33, 569-579.	3.9	42

#	Article	IF	CITATIONS
73	Awareness and opinions of nonâ€ a lcoholic fatty liver disease by hospital specialists. Internal Medicine Journal, 2013, 43, 247-253.	0.8	55
74	Heterogeneity of fibrosis patterns in nonâ€alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. Liver International, 2013, 33, 624-632.	3.9	48
75	The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology, 2013, 62, 367-386.	2.9	377
76	<scp>BMI</scp> But Not Stage or Etiology of Nonalcoholic Liver Disease Affects the Diagnostic Utility of Carbohydrateâ€Deficient Transferrin. Alcoholism: Clinical and Experimental Research, 2013, 37, 1771-1778.	2.4	6
77	Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease. Gut, 2013, 62, 1625-1633.	12.1	87
78	A Corn Oil–Based Diet Protects Against Combined Ethanol and Ironâ€Induced Liver Injury in a Mouse Model of Hemochromatosis. Alcoholism: Clinical and Experimental Research, 2013, 37, 1619-1631.	2.4	6
79	Promoting regulation via the inhibition of DNAM-1 after transplantation. Blood, 2013, 121, 3511-3520.	1.4	47
80	Lung Parenchyma–Derived IL-6 Induces Alloantigen Specific Th17 Differentiation Within The Lung and Idiopathic Pneumonia Syndrome After Allogeneic Stem Cell Transplantation. Blood, 2013, 122, 2011-2011.	1.4	16
81	Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. Nature Medicine, 2012, 18, 135-142.	30.7	206
82	Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut, 2012, 61, 774-779.	12.1	242
83	Transplantation pathology. , 2012, , 853-933.		8
84	Identification and expansion of highly suppressive CD8+FoxP3+ regulatory T cells after experimental allogeneic bone marrow transplantation. Blood, 2012, 119, 5898-5908.	1.4	114
85	Macrophage secretory products induce an inflammatory phenotype in hepatocytes. World Journal of Gastroenterology, 2012, 18, 1732.	3.3	32
86	Immunophenotype of Ductular Reaction in Human Livers With HCV. Gastroenterology, 2011, 140, S-972.	1.3	0
87	Type I-IFNs control GVHD and GVL responses after transplantation. Blood, 2011, 118, 3399-3409.	1.4	64
88	No evidence of the unfolded protein response in patients with chronic hepatitis C virus infection. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 319-327.	2.8	16
89	Interleukinâ€32: A new proinflammatory cytokine involved in hepatitis C virusâ€ŧelated liver inflammation and fibrosis. Hepatology, 2011, 53, 1819-1829.	7.3	79
90	Ductular reactions in human liver: Diversity at the interface. Hepatology, 2011, 54, 1853-1863.	7.3	232

#	Article	IF	CITATIONS
91	Altered lipid metabolism in Hfe-knockout mice promotes severe NAFLD and early fibrosis. American Journal of Physiology - Renal Physiology, 2011, 301, G865-G876.	3.4	31
92	Suppression of Inflammatory Immune Responses in Celiac Disease by Experimental Hookworm Infection. PLoS ONE, 2011, 6, e24092.	2.5	105
93	Not every cell is as it seems: a role for ductular epithelial cells in fibrosis?. Gut, 2011, 60, 1-2.	12.1	3
94	Effect of Hookworm Infection on Wheat Challenge in Celiac Disease – A Randomised Double-Blinded Placebo Controlled Trial. PLoS ONE, 2011, 6, e17366.	2.5	188
95	Whole Genome Expression Array Profiling Highlights Differences in Mucosal Defense Genes in Barrett's Esophagus and Esophageal Adenocarcinoma. PLoS ONE, 2011, 6, e22513.	2.5	36
96	Soluble lymphotoxin is an important effector molecule in GVHD and GVL. Blood, 2010, 115, 122-132.	1.4	49
97	An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood, 2010, 116, 3955-3963.	1.4	410
98	Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood, 2010, 116, 819-828.	1.4	139
99	SOCS3 regulates graft-versus-host disease. Blood, 2010, 116, 287-296.	1.4	37
100	Risk Stratification for Early Esophageal Adenocarcinoma: Analysis of Lymphatic Spread and Prognostic Factors. Annals of Surgical Oncology, 2010, 17, 2494-2502.	1.5	86
101	Successful Immunotherapy of HCMV Disease Using Virus‧pecific T Cells Expanded from an Allogeneic Stem Cell Transplant Recipient. American Journal of Transplantation, 2010, 10, 173-179.	4.7	30
102	Metabolic Factors and Non-Alcoholic Fatty Liver Disease as Co-Factors in Other Liver Diseases. Digestive Diseases, 2010, 28, 186-191.	1.9	43
103	Detection of Clonally Expanded Hepatocytes in Chimpanzees with Chronic Hepatitis B Virus Infection. Journal of Virology, 2009, 83, 8396-8408.	3.4	61
104	Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology, 2009, 49, 418-425.	7.3	46
105	Hepatic progenitor cell-mediated regeneration and fibrosis: Chicken or egg?. Hepatology, 2009, 49, 1424-1426.	7.3	27
106	Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways. Liver Transplantation, 2009, 15, 1315-1324.	2.4	63
107	Nesidioblastosis as a cause of focal pancreatic 1111n-pentetreotide uptake in a patient with putative VIPoma: another differential diagnosis. Annals of Nuclear Medicine, 2009, 23, 497-499.	2.2	7
108	Hepatobiliary and pancreatic: Papillary cholangiocarcinoma. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 1893-1893.	2.8	0

#	Article	IF	CITATIONS
109	Combined approach for non-invasive measurement of liver pathology by MR. Journal of Hepatology, 2009, 51, 1083-1084.	3.7	1
110	Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. Journal of Hepatology, 2009, 51, 389-397.	3.7	156
111	Invariant natural killer T cell–natural killer cell interactions dictate transplantation outcome after α-galactosylceramide administration. Blood, 2009, 113, 5999-6010.	1.4	28
112	Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. Journal of Magnetic Resonance Imaging, 2008, 28, 937-945.	3.4	174
113	Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology, 2008, 48, 80-87.	7.3	64
114	Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma. Molecular Cancer, 2008, 7, 75.	19.2	52
115	Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis. Journal of Hepatology, 2008, 49, 1046-1054.	3.7	46
116	Recognition of Genetic Factors Influencing the Progression of Hepatitis C. Molecular Diagnosis and Therapy, 2008, 12, 209-218.	3.8	18
117	Genome-Wide Copy Number Analysis in Esophageal Adenocarcinoma Using High-Density Single-Nucleotide Polymorphism Arrays. Cancer Research, 2008, 68, 4163-4172.	0.9	79
118	Blocking Indoleamine Dioxygenase Activity Early After Rat Liver Transplantation Prevents Long-Term Survival But Does Not Cause Acute Rejection. Transplantation, 2008, 85, 1357-1361.	1.0	20
119	IFNÎ ³ differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. Blood, 2007, 110, 1064-1072.	1.4	159
120	Steatosis as a Cofactor in Other Liver Diseases: Hepatitis C Virus, Alcohol, Hemochromatosis, and Others. Clinics in Liver Disease, 2007, 11, 173-189.	2.1	44
121	Progressive Fibrosis in Nonalcoholic Steatohepatitis: Association With Altered Regeneration and a Ductular Reaction. Gastroenterology, 2007, 133, 80-90.	1.3	425
122	Confocal Endomicroscopy in the Evaluation of Celiac Disease-A Prospective Validation Study. Gastrointestinal Endoscopy, 2007, 65, AB332.	1.0	1
123	Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood, 2006, 108, 2485-2492.	1.4	121
124	Characterization of tumour-infiltrating lymphocytes and apoptosis in colitis-associated neoplasia: comparison with sporadic colorectal cancer. Journal of Pathology, 2006, 208, 381-387.	4.5	20
125	Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology, 2006, 44, 489-501.	7.3	326
126	Liver fluke-associated and sporadic cholangiocarcinoma: an immunohistochemical study of bile duct, peribiliary gland and tumour cell phenotypes. Journal of Clinical Pathology, 2006, 59, 1073-1078.	2.0	43

#	Article	IF	CITATIONS
127	Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut, 2006, 55, 529-535.	12.1	251
128	TGF-Î ² in allogeneic stem cell transplantation: friend or foe?. Blood, 2005, 106, 2206-2214.	1.4	136
129	Fibrosis correlates with a ductular reaction in hepatitis C: Roles of impaired replication, progenitor cells and steatosis. Hepatology, 2005, 41, 809-818.	7.3	322
130	Steatosis: Co-factor in other liver diseases. Hepatology, 2005, 42, 5-13.	7.3	347
131	Cytokine Expanded Myeloid Precursors Function as Regulatory Antigen-Presenting Cells and Promote Tolerance through IL-10-Producing Regulatory T Cells. Journal of Immunology, 2005, 174, 1841-1850.	0.8	128
132	A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C. Journal of Medical Genetics, 2005, 42, e45-e45.	3.2	44
133	Adiponectin and its receptors in patients with chronic hepatitis C. Journal of Hepatology, 2005, 43, 929-936.	3.7	90
134	Steatosis Is a Cofactor in Liver Injury in Hemochromatosis. Gastroenterology, 2005, 129, 1937-1943.	1.3	158
135	Dangerous Liaisons: The Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. Annals of Internal Medicine, 2005, 143, 753.	3.9	22
136	Nonalcoholic fatty liver disease: is all the fat bad?. Internal Medicine Journal, 2004, 34, 187-191.	0.8	37
137	CCR5-Δ32 mutation is strongly associated with primary sclerosing cholangitis. Genes and Immunity, 2004, 5, 444-450.	4.1	66
138	Chronic hepatitis C and steatosis. Current Hepatitis Reports, 2004, 3, 123-128.	0.3	21
139	Virus-specific CD8+ T lymphocytes within the normal human liver. European Journal of Immunology, 2004, 34, 1526-1531.	2.9	30
140	Steatosis and liver cell apoptosis in chronic hepatitis C: A mechanism for increased liver injury. Hepatology, 2004, 39, 1230-1238.	7.3	133
141	Increased mononuclear cell activation and apoptosis early after human liver transplantation is associated with a reduced frequency of acute rejection. Liver Transplantation, 2004, 10, 397-403.	2.4	5
142	Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut, 2004, 53, 413-419.	12.1	382
143	Chronic graft-versus-host disease after granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation: the role of donor T-cell dose and differentiation. Biology of Blood and Marrow Transplantation, 2004, 10, 373-385.	2.0	26
144	An approach to the surgical pathology of tumours and tumour-like conditions of the liver. Pathology, 2004, 36, 5-18.	0.6	2

#	Article	IF	CITATIONS
145	Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. Blood, 2004, 103, 3573-3581.	1.4	133
146	Steatosis in chronic hepatitis C: Association with increased messenger RNA expression of collagen I, tumor necrosis factorâ€Î± and cytochrome P450 2E1. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 386-392.	2.8	72
147	Tumor progression in hepatocellular carcinoma: Relationship with tumor stroma and parenchymal disease. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 666-672.	2.8	35
148	In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. Journal of Hepatology, 2003, 39, 1042-1048.	3.7	157
149	Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation. Blood, 2003, 101, 2033-2042.	1.4	64
150	Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut, 2002, 51, 89-94.	12.1	259
151	Lymphocyte apoptosis and cell replacement in human liver allografts. Transplantation, 2002, 73, 1828-1834.	1.0	16
152	Cyclosporin A pretreatment in a rat model of warm ischaemia/reperfusion injury. Journal of Hepatology, 2002, 36, 241-247.	3.7	26
153	Fibrosis in chronic hepatitis C correlates significantly with circulating insulin levels. Journal of Hepatology, 2002, 36, 172.	3.7	2
154	Weight reduction in patients with chronic HCV reduces circulating insulin levels. Journal of Hepatology, 2002, 36, 255-256.	3.7	0
155	Interaction of non-alcoholic fatty liver disease with other liver diseases. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2002, 16, 767-781.	2.4	47
156	Angiotensin-Converting Enzyme Inhibition Attenuates the Progression of Rat Hepatic Fibrosis. Gastroenterology, 2001, 121, 148-155.	1.3	276
157	Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. Journal of Hepatology, 2001, 34, 314-320.	3.7	133
158	Role of cytokine gene polymorphisms in acute rejection and renal impairment after liver transplantation. Liver Transplantation, 2001, 7, 255-263.	2.4	28
159	Host genetic factors influence disease progression in chronic hepatitis C. Hepatology, 2000, 31, 828-833.	7.3	369
160	Increased hepatic iron and cirrhosis: No evidence for an adverse effect on patient outcome following liver transplantation. Hepatology, 2000, 32, 1200-1207.	7.3	46
161	Fibrous obliterative lesions of veins contribute to progressive fibrosis in chronic liver allograft rejection. Hepatology, 2000, 32, 1240-1247.	7.3	42
162	Detection of male DNA in the liver of female patients with primary biliary cirrhosis. Journal of Hepatology, 2000, 33, 690-695.	3.7	86

#	Article	IF	CITATIONS
163	Expression of cytokines and factors modulating apoptosis by human sinusoidal leucocytes. Journal of Hepatology, 2000, 32, 392-398.	3.7	16
164	CLINICOPATHOLOGICAL ANALYSIS OF LIVER ALLOGRAFT BIOPSIES WITH LATE CENTRILOBULAR NECROSIS. Transplantation, 2000, 69, 1599-1608.	1.0	34
165	Spur cell anaemia and hepatic iron stores in patients with alcoholic liver disease undergoing orthotopic liver transplantation. Gut, 1999, 45, 301-305.	12.1	57
166	C ASE R EPORT: Lamivudine therapy for submassive hepatic necrosis due to reactivation of hepatitis B following chemotherapy. Journal of Gastroenterology and Hepatology (Australia), 1999, 14, 801-803.	2.8	27
167	Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology, 1999, 29, 1215-1219.	7.3	623
168	ROLE OF DONOR LEUKOCYTE CHIMERISM IN ESTABLISHING THE ETIOLOGY OF NEUTROPENIA AFTER LIVER TRANSPLANTATION1. Transplantation, 1999, 67, 1358-1361.	1.0	6
169	Coincidental Splenectomy in Chronic Fatigue Syndrome. The Journal of Chronic Fatigue Syndrome: Multidisciplinary Innovations in Researchory and Clinical Practice, 1998, 4, 37-42.	0.4	0
170	PERSISTENCE OF DONOR-REACTIVE CD4+ T CELLS IN LIVER AND SPLEEN OF RATS TOLERANT TO A LIVER ALLOGRAFT1. Transplantation, 1998, 66, 132-135.	1.0	19
171	Evidence that "myofibroblast-like―cells are the cellular source of capsular collage in hepatocellular carcinoma. Journal of Hepatology, 1997, 26, 798-807.	3.7	83
172	Peripheral blood chimerism following human liver transplantation. Hepatology, 1997, 25, 1233-1236.	7.3	55
173	Eosinophilic Enteritis in Northeastern Australia. American Journal of Surgical Pathology, 1995, 19, 328-337.	3.7	86
174	GAMMA GLUTAMYL TRANSFERASE AS A MARKER OF LIVER TRANSPLANT REJECTION. Transplantation, 1994, 57, 1278-1280.	1.0	11